Reston, VA—Total body PET/CT scans can successfully visualize systemic joint involvement in patients with autoimmune arthritis, according to new first-in-human research published in the October issue of The Journal of Nuclear Medicine. The total body PET/CT scans showed high agreement with standard joint-by-joint rheumatological evaluation and a moderate to strong correlation with rheumatological outcome measures.
Autoimmune inflammatory arthritides (AIA)—such as psoriatic arthritis and rheumatoid arthritis—are chronic, systemic conditions that cause joint inflammation, joint destruction and pain. According to the Centers for Disease Control and Prevention, approximately one in four adults, or 58 million Americans, have been diagnosed with arthritis by a doctor. By 2040, an estimated 78 million adults are projected to be diagnosed with arthritis.
“Currently, there are significant clinical challenges in managing AIA populations. For example, it is unclear which patients should receive which treatments, how exactly these treatments change the inflammatory status of different tissues or outcomes, and the impact the disease and treatments have on other organs of the body,” said Abhijit J. Chaudhari, PhD, professor of radiology at the University of California–Davis in Davis, California. “Systemic molecular imaging enabled by total body PET could provide currently unavailable, objective biomarkers that could help address these challenges.”
To assess the performance of molecular imaging to evaluate AIA, researchers used an ultra-low dose 18F-FDG total-body PET/CT acquisition protocol to scan 30 participants (24 with AIA and six with osteoarthritis). Participants also underwent a joint-by-joint rheumatological evaluation. In total, 1,997 joints were evaluated.
Total body PET/CT was successful in visualizing 18F-FDG uptake at joints throughout the entire body, including those of the hands and feet, without the need for custom positioning of the participants. In the AIA cohort, there was concordance between total body PET qualitative assessments and joint-by-joint rheumatological evaluation for 69.9 percent of the participants. About 20 percent of the AIA group had joints that were deemed negative on rheumatological evaluation but were positive on PET/CT, and 10 percent were negative on PET/CT but positive on the rheumatological evaluation. For the osteoarthritis cohort, there was agreement in joint assessment among 91.1 percent of participants. In this group 8.8 percent of joints were deemed negative on rheumatological evaluation but were positive on PET/CT, and no joints were negative on PET/CT but positive on rheumatological exam.
“Systemic evaluation of arthritic disease activity across all musculoskeletal tissues of the body may provide unique insights for assessing disease burdenrisk stratification, treatment selection, and monitoring on treatment response. The biomarkers imaged may also have clear potential to accelerate arthritic drug discovery and development,” noted Chaudhari. “In addition, the inflammatory arthritides assessed in the paper are part of a broad category of autoimmune disorders. This work may contribute to improved understanding of total-body impact of autoimmunity.”
The authors of “Total-Body 18F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations” include Yasser Abdelhafez, Department of Radiology, University of California Davis, Davis, California, and Nuclear Medicine Unit, South Egypt Cancer Institute, Assiut University, Egypt; Siba P. Raychaudhuri, Department of Internal Medicine-Rheumatology, University of California Davis, Davis, California, and Northern California Veterans Affairs Medical Center, Mather, California; Dario Mazza, Heather L. Hunt, Kristin McBride, Mike Nguyen, Denise T. Caudle, Lorenzo Nardo and Abhijit J. Chaudhari, Department of Radiology, University of California Davis, Davis, California; Soumajyoti Sarkar, Department of Internal Medicine-Rheumatology, University of California Davis, Davis, California; Benjamin A. Spencer, Negar Omidvari, Simon Cherry and Ramsey D. Badawi, Department of Radiology, University of California Davis, Davis, California, and Department of Biomedical Engineering, University of California Davis, Davis, California; and Heejung Bang, Department of Public Health Sciences, University of California Davis, Davis, California.
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or firstname.lastname@example.org.
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.
Journal of Nuclear Medicine
Total-Body 18F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations
Article Publication Date
University of California Davis has a research and a revenue-sharing agreement with United Imaging Health Care. Ramsey D. Badawi, Simon R. Cherry, and Lorenzo Nardo are investigators on a research grant funded by United Imaging Health Care, the manufacturer of the scanner used in this article.